Deutsche Bank AG Invests $4.30 Million in ICU Medical, Inc. $ICUI

Deutsche Bank AG acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,348 shares of the medical instruments supplier’s stock, valued at approximately $4,302,000.

Several other institutional investors have also bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of ICU Medical in the second quarter valued at $26,966,000. Oppenheimer Asset Management Inc. bought a new stake in ICU Medical during the 2nd quarter valued at $347,000. Revolve Wealth Partners LLC purchased a new position in shares of ICU Medical in the second quarter valued at $243,000. Reinhart Partners LLC. purchased a new position in ICU Medical during the 2nd quarter valued at about $46,148,000. Finally, Bank of America Corp DE grew its stake in ICU Medical by 11.2% during the first quarter. Bank of America Corp DE now owns 331,739 shares of the medical instruments supplier’s stock valued at $42,844,000 after acquiring an additional 33,508 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Stock Down 0.2%

ICUI stock opened at $182.24 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The company has a market capitalization of $4.55 billion, a price-to-earnings ratio of 154.44, a price-to-earnings-growth ratio of 2.31 and a beta of 0.74. The business’s 50 day moving average price is $162.42 and its two-hundred day moving average price is $143.53. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts forecast that ICU Medical, Inc. will post 7.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Elisha W. Finney sold 378 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the transaction, the director directly owned 4,871 shares of the company’s stock, valued at approximately $888,860.08. This represents a 7.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the transaction, the insider directly owned 3,076 shares in the company, valued at approximately $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 16,974 shares of company stock valued at $3,085,844. 2.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of recent analyst reports. Piper Sandler increased their price objective on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Needham & Company LLC increased their target price on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday, August 7th. BTIG Research raised their price target on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.